Wednesday, July 8, 2026

Patent intelligence · US

US 11129869

Pharmaceutical compositions

granted A61KA61K38/08A61K38/12A61K45/06
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 15
Applicant portfolio 12
Patent details — US 11129869
Jurisdiction
US
Status
granted
Grant date
Sep 28, 2021
Expiration
Sep 23, 2041
Claims
24
CPC classes
A61K, A61K38/08, A61K38/12, A61K45/06
View on Google Patents ↗

Quick answer

US 11129869 (Pharmaceutical compositions) is held by RHYTHM PHARMACEUTICALS, INC.. Status: granted. Granted Sep 28, 2021. Expires Sep 23, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
24
CPC classes
A61K, A61K38/08, A61K38/12, A61K45/06, A61K47/10, A61K47/12

More from RHYTHM PHARMACEUTICALS, INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12285460

    Pharmaceutical compositions

    RHYTHM PHARMACEUTICALS, INC. · Expires Apr 24, 2045

    granted
  2. US 12263202

    Method of treating melanocortin-4 receptor pathway-associated disorders

    RHYTHM PHARMACEUTICALS, INC. · Expires Mar 27, 2045

    granted
  3. US 12077612

    Peptide compositions

    RHYTHM PHARMACEUTICALS, INC. · Expires Aug 29, 2044

    granted
  4. US 11702448

    Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

    RHYTHM PHARMACEUTICALS, INC. · Expires Jul 13, 2043

    granted
  5. US 10960046

    Method of treating melanocortin-4 receptor pathway-associated disorders

    RHYTHM PHARMACEUTICALS, INC. · Expires Mar 25, 2041

    granted
  6. US 10954268

    Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers

    RHYTHM PHARMACEUTICALS, INC. · Expires Mar 18, 2041

    granted
  7. US 10858399

    Peptide compositions

    RHYTHM PHARMACEUTICALS, INC. · Expires Dec 3, 2040

    granted

Frequently asked questions

What is US patent 11129869?

US 11129869 (Pharmaceutical compositions) is held by RHYTHM PHARMACEUTICALS, INC.. Status: granted. Granted Sep 28, 2021. Expires Sep 23, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11129869?

RHYTHM PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 12 pharmaceutical patents for this assignee.

When does US 11129869 expire?

Our index shows an expiration date of Sep 23, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.